AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

The U.K.-based drugmaker plans to invest $50 billion in the United States as the industry seeks to appease President Trump.

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on ...

The biopharmaceutical company AstraZeneca announced it will $50 billion into the United States, with plans to open several ...

AstraZeneca said the “cornerstone” of the commitment would be a new weight management production facility for its oral GLP-1 ...

The biopharmaceutical company said the investment includes plans for a new manufacturing center focused on chronic diseases.

British-Swedish pharmaceutical company AstraZeneca announced a $50 billion investment in the U.S. this week, with the Trump ...

That’s how long it took from the time AstraZeneca CEO Pascal Soriot greeted Virginia Governor Glenn Youngkin in his London ...

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030.

AstraZeneca (AZN) stock is in focus as the company's experimental drug gefurulimab for generalized myasthenia gravis hits ...

Governor Glenn Youngkin spoke with 8News about AstraZeneca’s recent announcement to build their world’s-largest manufacturing ...

The investment will fund a new drug manufacturing facility in Virginia, and expand research and development in at least 5 ...